Table 1.
Demographic data of study population.
| Total (n = 73) |
1st QFT-GIT(+) (n = 49) |
1st QFT-Plus(+) (n = 47) | p value‡ | |
|---|---|---|---|---|
| Age | 56.7 ± 11.2 | 57.7 ± 11.1 | 57.4 ± 11.6 | 0.766 |
| Sex, male n (%) | 52 (71) | 35 (71) | 33 (70) | 1 |
| Dialysis, HD* n (%) | 59 (81) | 36 (73) | 37 (79) | 0.635 |
| DM n (%) | 15 (21) | 12 (25) | 14 (30) | 0.648 |
| Rheumatoid n (%) | 1 (1) | 1 (2) | 1 (2) | 1 |
| Previous TB n (%) | 4 (6) | 2 (4) | 3 (6) | 0.674 |
| BCG scar# n (%) | 65 (89) | 44 (90) | 41 (97) | 0.757 |
| QFT-GIT0†, IU/ml | 2.31 ± 2.40 | 2.65 ± 2.36 | 2.93 ± 2.38 | 0.914 |
| LTBI treatment n (%) | 57 (75) | 38 (78) | 35 (75) | 0.182 |
Data are presented as number (percentage) or mean ± standard deviation.
None had underlying cancer or cirrhosis.
BCG, Bacillus Calmette-Guérin vaccine; DM, diabetes mellitus; M, male; HD, hemodialysis; LTBI, latent tuberculosis infection; QFT-GIT, QuantiFERON-TB Gold In-Tube; QFT-Plus, QuantiFERON-TB Gold Plus; TB, tuberculosis.
*Regarding dialysis modality, those not receiving hemodialysis received peritoneal dialysis.
#Missing data of BCG: four patients in the total population; two patients in the 1st QFT-GIT(+) group and two in the 1st QFT-Plus(+) group, respectively.
†QFT-GIT0: the interferon-gamma level of the TB Antigen tube minus the negative control tube at the baseline test of the QuantiFERON-TB Gold In-Tube.
‡p values were compared between patients with 1st QFT-GIT(+) and those with 1st QFT-Plus(+).